The Food and Drug Administration (FDA) proposed a tobacco product standard for N-nitrosonornicotine (NNN) in smokeless tobacco products. In order to fulfill the proposed tobacco product standard, all measurements of NNN need (in effect) to be performed with a newly developed standard test method developed by the FDA, Office of Regulatory Affairs, Southeast Regional Laboratory (Laboratory Information Bulletin (LIB) 4620).

Although based on CORESTA Recommended Method No. 72, the proposed FDA validated method has not been evaluated in a robust collaborative study involving stakeholders and has disadvantages compared to CRM 72, which is currently being processed as ISO/CD 21766.

On 10 April 2017, CORESTA provided comments to the FDA by comparing the two methods (see section Information > CORESTA Communication > Regulatory Affairs).